What smart money is saying about Abbott Labs
6 funds in our archive have pitched Abbott Labs, most recently Longleaf Partners Global Fund in September 2026.
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Get an email when a fund buys, sells or pitches it
Fund signal · last 12 months
12 lettersFunds are split between buying and selling
Moves described in fund letters in our archive. A sentence published word for word by several funds of one house in the same quarter counts once.
Position history
Between Q1 2025 and Q3 2026, 13 fund letters reported a position in Abbott Labs, with 3 buys (opened or added) and 4 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 3 | 1 | 0 | 2 |
| Q2 2026 | 8 | 2 | 2 | 0 |
| Q1 2026 | 1 | 0 | 1 | 3 |
| Q4 2025 | 0 | 0 | 0 | 1 |
| Q1 2025 | 1 | 0 | 1 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 13 positions · 8 moves
- New positionLongleaf Partners FundSeptember 2026
“Abbott Labs – This diversified healthcare company is a new holding (owned previously in the 2010s) and is off to a strong start for us.”
Abbott Labs - New positionLongleaf Partners Global FundSeptember 2026
“Abbott Labs – This diversified healthcare company is a new holding (owned previously in the 2010s) and is off to a strong start for us.”
Abbott Labs - September 2026
“• Shares of diversified health care company Abbott Laboratories outperformed following better-than-expected second-quarter results, improving trends in its nutrition and diagnostics business, and higher full-year earnings guidance.”
Abbott Labs - New positionMatrix Asset Advisors Capital Markets CommentaryJune 2026
“During the quarter, we started new partial positions in Abbott Laboratories (ABT) and McDonald’s (MCD).”
Abbott Labs - June 2026
“In Health Care, we rebalanced within the sector, exiting Bio- Rad Laboratories and adding to Abbott Laboratories, a medical device leader that we believe offers greater upside, supported by product innovation and demographic-driven demand.”
Abbott Labs “The leading individual Portfolio detractors during the quarter were Abbott Laboratories (ABT) and Broadridge Financial Solutions (BR).”
Abbott Labs- June 2026
“Chevron was negatively impacted by a U.S.-Iran memorandum of understanding that reopened tanker traffic through the Strait of Hormuz, easing global oil supply constraints and sending oil prices down 31% during the quarter amid ongoing longer-term negotiations. Abbott Laboratories, a manufacturer of diagnostic products, nutritional products and medical devices, reported slightly lower growth expectations from its legacy businesses, including disruptions in the Middle East due to the ongoing Iran conflict and a weaker flu season that led to lower than expected diagnostics growth.”
Abbott Labs “Abbott Laboratories, a manufacturer of diagnostic products, nutritional products and medical devices, reported slightly lower growth expectations from its legacy businesses, including disruptions in the Middle East due to the ongoing Iran conflict, and a weaker flu season that led to lower than expected diagnostics growth.”
Abbott Labs- June 2026
“Seven positions were eliminated from the portfolio during the quarter.”
Abbott Labs - ExitedBurke Wealth Management Focused Growth StrategyJune 2026
“Q2 PORTFOLIO ACTIVITY The second quarter was an active trading quarter in our Focused Growth portfolio. We sold our positions in Abbott Labs and Lowe’s, added new positions in Eaton and Apollo, trimmed back rocket ship Micron twice for risk management purposes and used share price weakness as an opportunity to bolster our weightings in Intuitive Surgical, Meta, Service Now and Uber.”
Abbott Labs - April 2026
“Other detractors included the likes of Abott Laboratories (Health Care), Accenture (Information Technology) & Aon (Financials).”
Abbott Labs - ExitedPolen Focus GrowthMarch 2026
“At the same time, we exited our position in Abbott Laboratories during the quarter, following a prior reduction after the company announced its acquisition of Exact Sciences.”
Abbott Labs - ExitedVulcan VPMarch 2025
“We sold four positions during the quarter: Live Nation Entertainment Inc., Marriott International Inc., Fiserv Inc., and Abbott Laboratories.”
Abbott Labs
Fund coverage · 6 theses
- Longleaf Partners Global FundSeptember 2026
Abbott Labs is a diversified healthcare company with durable EPS growth, a safe dividend, downside protection, and potential upside from portfolio actions.
Read the full thesis - AcatisAugust 2026
Abbott Laboratories is a diversified health care leader with recurring growth, competitive advantages and an attractive valuation.
Read the full thesis - Alpha Wealth FundsMarch 2026
Abbott Laboratories is a diversified healthcare 'Dividend King' with insider-supported value and upside from Exact Sciences’ MCED integration.
Read the full thesis - The Davenport FundsMarch 2026
Abbott Laboratories is a diversified healthcare company with an expanded diagnostics market, accelerating growth guidance, and insider buying.
Read the full thesis - Bell Global Equities FundJanuary 2026
Abbott Laboratories is a diversified medtech leader with catalysts in Libre and PFA, enhanced oncology diagnostics, and an attractive entry after de-rating.
Read the full thesis - Parnassus Value Select ETFDecember 2025
Abbott Laboratories offers durable growth from leadership in diabetes, heart health, and electrophysiology, supported by innovation and a diversified global model.
Read the full thesis
Read every full thesis on Abbott Labs
Read all 6 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→